Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Xavier Leleu; Meral Beksaç; María‐Victoria Mateos; Luděk Pour; Katja Weisel; Daniel Coriu; Michaela Obreja; Amanda Goldrick; Meletios A Dimopoulos

doi:10.1016/j.clml.2019.07.324

Article2019

Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma

Xavier Leleu, Meral Beksaç, María‐Victoria Mateos, Luděk Pour, Katja Weisel, Daniel Coriu, Mihaela Obreja, Amanda Goldrick, Meletios A Dimopoulos

Article2018

Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

María‐Victoria Mateos, Philippe Moreau, James R. Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten‐Kumeli, A. Keith Stewart

Article2019

PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Philippe Moreau, A. Keith Stewart, Meletios A Dimopoulos, David S. Siegel, Thierry Façon, James Berenson, Noopur Raje, Jesús G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, M.‐V. Mateos

Article2018

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Meletios A Dimopoulos, Rubén Niesvizky, Philippe Moreau, David S. Siegel, Roman Hájek, María‐Victoria Mateos, Michèle Cavo, Mei Huang, Anita Zahlten‐Kumeli, Katja Weisel

Article2018

Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

Philippe Moreau, Shaji Kumar, Ralph V. Boccia, Shinsuke Iida, Hartmut Goldschmidt, Kim Cocks, Anita Zahlten‐Kumeli, Emre Yücel, Sumeet Panjabi, Meletios A Dimopoulos

Trial in Progress: Once-Weekly vs Twice-Weekly Carfilzomib (K) Dosing in Combination with Lenalidomide (R) and Dexamethasone (d) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Discussion(0)

Related publications

Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma

Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.

PF612 ONCE‐WEEKLY (70 MG/M2) VERSUS TWICE‐WEEKLY (56 MG/M2) DOSING OF CARFILZOMIB FOR PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)